10601 results for 'EGF Receptor Inhibitors'

Immunology · Antibody BiologyAntibody Light Chains, Heavy Chains, Constant Regions & Tumour-Associated AntigensAn antibody’s specificity comes from its variable domains and its biological effect comes

Quick Facts About CobolimabWhat is Cobolimab?Cobolimab is a monoclonal antibody that targets TIM-3, a checkpoint protein involved in immune regulation, especially in cancer and autoimmun

For decades, cancer drug development has focused on blocking proteins—inhibiting enzymes, antagonizing receptors, disrupting signaling pathways. Yet this approach leaves a vast landscape of disease-d

Quick Facts About UliledlimabWhat is Uliledlimab?Uliledlimab is a monoclonal antibody targeting CD47, a checkpoint protein that helps tumors evade immune system detection. By blocking CD

Quick Facts About DurvalumabWhat is Durvalumab?Durvalumab (Imfinzi) is a PD-L1 checkpoint inhibitor used in immunotherapy to treat various cancers, including non-small cell lung cancer (

Harnessing the immune system to fight cancer has become a pivotal strategy in modern oncology. A key component in this fight is CD27, a receptor that plays a crucial role in T-cell activa

What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c

Introduction to KIR Blockade in Cancer ImmunotherapyNatural killer (NK) cells are crucial components of the innate immune system, responsible for recognizing and destroying virally infec

What You Need to Know About LusvertikimabWhat is Lusvertikimab?Lusvertikimab is a monoclonal antibody designed to inhibit the IL-4 receptor, a key player in regulating immune responses,

Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance

Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab

In the realm of immunotherapy, T cell expansion has emerged as a pivotal strategy, holding promise in the treatment of various diseases, particularly cancer. T cells are a critical component of

The most abundant immunosuppressive molecule in a solid tumour is not a protein. It is adenosine — a metabolite, produced from ATP in two enzymatic steps, at concentrations orders of magnitude above

Quick Facts About Ladiratuzumab VedotinWhat is Ladiratuzumab Vedotin?Ladiratuzumab Vedotin is an antibody-drug conjugate (ADC) designed to target LIV-1, a protein commonly expressed in t

Targeting USP22: A New Approach to Enhance Anticancer Immunity Introduction In the ever-evolving landscape of cancer research, the intricate relationship between immune e

Nod-like receptors Nod like receptors (NLRs) are a versatile family of relatively recently discovered intracellular receptors which have a br

For decades, the fight against cancer has been a relentless battle of attrition, often with treatments that harm the body as much as the disease. But a new era of precision medicine is dawning, one th

Introduction to SLAMF7 in Cancer Immunotherapy SLAMF7, also known as Signaling Lymphocytic Activation Molecule F7, is a surface receptor found on natural killer (NK) cells, T cells, plasm

Immunology · CytokinesIFN-gamma: Signalling, Function and Roles in Inflammation, Cancer and AutoimmunityInterferon gamma is the sole type II interferon and one of the most consequential cytokines in i